GlassScriptPhysician profile
Farzaneh Farzin
NPI 1154339778
$12,344.40
in general payments reported to CMS, 2019-2025
51 companies · $3,015 in 2025
The $3,015 reported for 2025 was more than what 93% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $3,374 · 2021: $306 · 2022: $981 · 2023: $1,756 · 2024: $2,313 · 2025: $3,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,084.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,742.94 | 2019-2025 | Imfinzi, Saphnelo, Tagrisso |
| Daiichi Sankyo INC. | $1,306.83 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Regeneron Healthcare Solutions, INC. | $1,052.38 | 2019-2025 | Libtayo, Lynozyfic |
| Novartis Pharmaceuticals Corporation | $975.70 | 2022-2025 | |
| Exelixis INC. | $444.60 | 2021-2025 | Cabometyx |
| Incyte Corporation | $427.37 | 2021-2024 | Monjuvi, Jakafi |
| Sobi, INC | $350.10 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $319.69 | 2022-2023 | Pylarify |
| Merck Sharp & Dohme LLC | $250.57 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Hologic INC | $211.42 | 2020 | |
| Amgen INC. | $208.23 | 2022-2023 | Nplate, Kyprolis, Xgeva |
| Visionrt, INC. | $199.25 | 2019 | |
| Beigene USA, INC. | $197.44 | 2024-2025 | Brukinsa |
| Janssen Biotech, INC. | $188.50 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| Abbvie INC. | $166.94 | 2019-2023 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $151.39 | 2023-2025 | Voranigo |
| Regeneron Pharmaceuticals, INC. | $148.95 | 2025 | Libtayo |
| Galderma Laboratories, L.P. | $142.32 | 2024 | |
| Ucb, INC. | $125.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.58 | 2021-2025 | |
| Novo Nordisk INC | $124.57 | 2025 | Wegovy |
| Icotec Medical INC. | $123.74 | 2024 | Vader Pedicle System |
| Genentech USA, INC. | $111.61 | 2022-2025 | Tecentriq, Itovebi, Polivy |
| Genzyme Corporation | $110.48 | 2022-2024 | |
| Novocure INC. | $109.66 | 2020-2022 | |
| Geron Corporation | $106.80 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $94.57 | 2024-2025 | Xpovio |
| Emd Serono, INC. | $88.16 | 2023-2025 | Tepmetko, Bavencio |
| Sumitomo Pharma America, INC. | $75.18 | 2023-2025 | Orgovyx |
| Coherus Oncology, INC. | $68.61 | 2024-2025 | Loqtorzi |
| Beone Medicines USA, INC. | $53.16 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $49.51 | 2025 | Orserdu |
| Celgene Corporation | $47.40 | 2022-2023 | Reblozyl |
| Dendreon Pharmaceuticals LLC | $45.12 | 2024 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $42.94 | 2024-2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $40.67 | 2025 | Jemperli |
| Seagen INC. | $36.56 | 2023 | Padcev |
| Lilly USA, LLC | $26.08 | 2025 | Verzenio, Jaypirca |
| Reflexion Medical, INC. | $25.00 | 2023 | Reflexion Medical Radiotherapy System |
| Array Biopharma INC | $23.25 | 2024 | Braftovi |
| Sun Pharmaceutical Industries INC. | $22.95 | 2022 | |
| Mirati Therapeutics, INC. | $22.48 | 2023 | Krazati |
| Agios Pharmaceuticals, INC. | $22.14 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $21.67 | 2025 | Tivdak |
| Sirtex Medical INC | $18.49 | 2023 | Sir-Spheres Microspheres |
| Puma Biotechnology, INC. | $18.29 | 2023 | |
| Eisai INC. | $18.25 | 2022 | |
| Astellas Pharma US INC | $17.90 | 2024 | Padcev |
| Pfizer INC. | $16.69 | 2024 | |
| Forte Bio-Pharma LLC | $15.17 | 2023 | Prolate, Nalocet |
| Taiho Oncology, INC. | $13.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzaneh Farzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.